176results about How to "Efficient modulation" patented technology

The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or noncarrier.

The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a nonbiodegradable microcarrier or nanocarrier.

Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

The present invention relates to an orally available galenics formulation of Valproic Acid or derivatives thereof exhibiting a specific bi-phasic pharmacokinetic profile optimized for maximum inhibition of histone deacetylases in a therapeutic setting. This specific galenics formulation is designed for the treatment of malignant diseases and diseases associated with hypoacetylation of histones or in which induction of hyperacetylation has a beneficial effect, e.g., by induction of differentiation and/or apoptosis. Due to the bi-phasic release pattern the resulting pharmacokinetic profile is able to inhibit HDAC target enzymes most efficiently and to subsequently induce histone hyperacetylation in a rapid as well as a long-lasting fashion. This profile secures the efficient modulation of a desired target gene expression profile which contributes to the therapeutic benefit.

The invention relates to a laser radar system. The laser radar system comprises a light emitting unit, a light receiving unit and a control unit, wherein the light emitting unit comprises a light source and a scanning unit, and the scanning unit is configured to reflect light from the light source at a controllable deflection angle to scan a target object; the light receiving unit is used for receiving the light reflected from the target object and outputting a detection value, and the light receiving unit comprises a photoelectric sensor device; and a light path from the light emitted by thelight emitting unit to the target object is non-coaxial with a light path from the light reflected from the target object to the light receiving unit. According to the laser radar system, the defect that an SPAD detector in an optical sensor cannot eliminate dark counts in the prior art is overcome; distance information of a surrounding three-dimensional space environment can be accurately measured; and the influence of background light and other stray light can be greatly inhibited, so that spatial light can be quickly and efficiently modulated.

The present invention provides methods (assays) for detecting and/or quantifying sAPPβ, a secreted β-secretase (BACE1) cleavage fragment of the β-amyloid precursor protein (APP), in a biological sample. One such method includes contacting a biological sample with a first antibody that selectively binds to a BACE1 cleavage site on sAPPβ and detecting the presence of the antibody. Also provided are compositions, including antibodies that selectively bind to the BACE1 cleavage site of sAPPβ. Kits containing such compositions are also provided. Methods of diagnosing a neurodegenerative disease, such as AD, using the methods and compositions of the present invention are further provided. Methods for identifying BACE1 modulators, candidate compounds that are BACE1 modulators, and methods for treating, preventing or ameliorating neurodegenerative disease, such as AD, using such compounds or pharmaceutical compositions containing such compounds are also provided.

A remote communications terminal accesses a terrestrial network or information source via a SATCOM link with an earth station hub linked to the network or information source. Information throughput adaptation (ITA) is employed on the SATCOM link to maximize information throughput over the SATCOM link while ensuring acceptable signal quality under varying rain fading conditions. Sufficient power margin is built into the SATCOM link such that, under severe rain fading conditions, the lowest system throughput rate still provides acceptable signal quality. Under lesser rain fading conditions, the data throughput rate is increased via more bandwidth efficient modulation and coding schemes permitted by the higher signal quality which results from greater power margin. The earth station hub and remote terminals monitor the signal quality and communicate to adaptively adjust the modulation and coding used on the forward and return links to maximize information throughput under varying rain fading conditions.

The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.

Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.

A modulation circuit for a traffic surveillance Doppler radar system is disclosed. In one embodiment, the modulation circuit is utilized in a vehicular traffic surveillance Doppler radar system that processes a reflected double-modulated FM signal to determine a target range based upon a phase angle signal differential associated with the target. The modulation circuit may include a digital-to-analog (D/A) converter/voltage regulator/oscillator arrangement or a D/A converter/varactor device/oscillator arrangement. The modulation circuit generates a double-modulated FM signal based upon a frequency versus voltage characteristic associated with the oscillator.

A modulated carrier signal is produced from a phase modulation signal in a phase locked loop in a polar modulator. This carrier signal is converted via a limiting amplifier to a square-wave signal, which is supplied to an amplifier. At the same time, an amplitude modulation signal at one input is connected to a control input of a controllable current source. The controllable current source is designed to emit a supply current at a current output as a function of the amplitude modulation signal at the control input. The current output of the controllable current source is connected to a supply input of the amplifier. The supply current for the amplifier is thus modulated on the basis of the amplitude information to be transmitted. The processing of the amplitude information within the current domain makes it possible to produce the polar modulator according to the invention as an integrated circuit, using CMOS technology.

The nitride semiconductor material according to the present invention includes a group III nitride semiconductor and a group IV nitride formed on the group III nitride semiconductor, where an interface between the group III nitride semiconductor and the group IV nitride has a regular atomic arrangement. Moreover, an arrangement of nitrogen atoms of the group IV nitride in the interface and an arrangement of group III atoms of the group III nitride semiconductor in the interface may be substantially identical.

In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.